Stemirna Therapeutics
PrivateLast Round
Series D
May 25, 2023
Est. Valuation
$308.9M
Total Funding Raised
$238.5M
Company Overview
Stemirna Therapeutics operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series D round in May 2023.
Stemirna Therapeutics is a biotechnology company that develops mRNA-based vaccines and therapeutics for infectious diseases and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Stemirna Therapeutics Comparables
Compare Stemirna Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shanghai RNACure Biopharma Co., Ltd. | 87% | |
| Abogen Biosciences | 86% | |
| WestGene Biopharma | 86% |
For institutional investors. Book with your work email.
Stemirna Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | May 25, 2023 | ||||
| Strategic | Aug 27, 2021 | ||||
| Series C | Jun 1, 2021 | ||||
| Series B | Dec 1, 2020 | ||||
| Series A Extension | Feb 7, 2020 | ||||
Series A | Jul 1, 2019 |
For institutional investors. Book with your work email.
Stemirna Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 招银国际金融有限公司 | Series C |
| Shanghai Zhangjiang Torch Venture Capital | Series A |
| Greenwoods Investments | Series C |
| OrbiMed | Series C |
| Forebright Capital | Series C |
| Advantech Capital | Series C |
| CITIC Securities Investment | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 1, 2021
$188M round led by Greenwoods Investments and WuXi AppTec.
- Feb 7, 2020
$4.3M round with participation from LC Ventures
For institutional investors. Book with your work email.
Stemirna Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Stemirna Therapeutics's valuation, stock price, and market status.
Is Stemirna Therapeutics a public or private company?
Stemirna Therapeutics is a private company.
What is the current stock price of Stemirna Therapeutics?
Stemirna Therapeutics is a private company, so its shares have no public market price. Caplight tracks Stemirna Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Stemirna Therapeutics worth (valuation)?
Stemirna Therapeutics's valuation is estimated at $308.9M based on funding round data.
Can I buy Stemirna Therapeutics stock?
Stemirna Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Stemirna Therapeutics's last funding round?
Stemirna Therapeutics's most recent funding round was Series D on May 25, 2023.
Who are the main investors in Stemirna Therapeutics?
Key investors in Stemirna Therapeutics include Greenwoods Investments, HongShan Capital Group (HSG).
Will Stemirna Therapeutics IPO soon?
No public IPO plans have been announced for Stemirna Therapeutics.
How can I track Stemirna Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Stemirna Therapeutics's shares on secondary markets.